RT Book, Section
A1 Mittendorf, Elizabeth A.
A1 Czerniecki, Brian J.
A1 Peoples, George E.
A2 Kuerer, Henry M.
SR Print(0)
ID 6417577
T1 Chapter 91. Breast Cancer Vaccines
T2 Kuerer's Breast Surgical Oncology
YR 2010
FD 2010
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-160178-8
LK accesssurgery.mhmedical.com/content.aspx?aid=6417577
RD 2023/03/21
AB Advances  in  the  molecular  characterization  of  human  tumors  have  led  to  increased  interest  in  the  development  of  targeted  therapeutics  to  include  monoclonal  antibodies  and  cancer  vaccines.  Interest  in  the  development  of  cancer  vaccines  has  increased  since  these  advances  led  to  the  identification  of  tumor-associated  antigens  (TAAs).1-3  TAAs  expressed  by  tumors  are  able  to  elicit  a  specific  immune  response.  In  addition  to  having  an  antigen  that  serves  as  a  target  for  the  immune  response,  a  successful  tumor  vaccine  requires  a  platform  to  present  the  antigen  to  the  immune  system  and  an  environment  that  is  conducive  to  immune  stimulation.  The  goal  of  researchers,  therefore,  has  been  to  identify  TAAs  and  deliver  them  to  the  immune  system  in  the  context  of  a  vaccine  with  the  appropriate  secondary  signals  required  to  prompt  a  robust,  protective  immune  response.